Literature DB >> 27300749

Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia.

Qiuju Tian1, Jidong Jia2.   

Abstract

Hepatitis B virus (HBV) is characterized by a high genetic heterogeneity since it replicates via a reverse transcriptase that lacks proofreading ability. Up to now, ten genotypes (A-J) have been described, with genotype A and D being ubiquitous but most prevalent in Europe and Africa, genotype B and C being confined to Asia and Oceania. Infections with other genotypes such as E, F, G and H are also occasionally observed in Asia. Genotype I is rare and can be found in Laos, Vietnam, India and China, whereas genotype J has been described in Japan and Ryukyu. Novel variants generated by recombination and co-infection with other genotypes have gradually gotten worldwide attention and may be correlated with certain clinical features. There are substantial differences in HBV infection regarding prevalence, clinical manifestation, disease progression and response to antiviral therapy. Due to the complex interplay among viral, host and environmental factors, the relationship between HBV genotypes and clinical profiles remains incompletely revealed. In general, genotype A is associated with better response to interferon therapy; genotype C, and to lesser extent B, usually represent a risk factor for perinatal infection and are associated with advanced liver diseases such as cirrhosis and hepatocellular carcinoma; genotype D may be linked with poor response to interferon therapy. Future studies with better design and larger sample size are warranted to further clarify the controversial issues and guide the day-to-day clinical practice.

Entities:  

Keywords:  Antiviral therapy; Asia; Genotype; Hepatitis B virus; Hepatocellualr carcinoma; Review

Mesh:

Substances:

Year:  2016        PMID: 27300749     DOI: 10.1007/s12072-016-9745-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  64 in total

1.  Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma.

Authors:  Hongli Yan; Yuan Yang; Ling Zhang; Guannan Tang; YuZhao Wang; Geng Xue; Weiping Zhou; Shuhan Sun
Journal:  Hepatology       Date:  2015-03-18       Impact factor: 17.425

2.  Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases.

Authors:  Seoung-Ae Lee; Kijeong Kim; Hong Kim; Bum-Joon Kim
Journal:  J Hepatol       Date:  2011-08-07       Impact factor: 25.083

3.  Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

Authors:  Teerha Piratvisuth; George Lau; You-Chen Chao; Rui Jin; Anuchit Chutaputti; Q-B Zhang; Tawesak Tanwandee; Peter Button; Matei Popescu
Journal:  Hepatol Int       Date:  2008-02-05       Impact factor: 6.047

4.  Hepatitis B virus genotypes and genome characteristics in China.

Authors:  Hong-Mei Li; Jian-Qiong Wang; Rui Wang; Qian Zhao; Li Li; Jin-Ping Zhang; Tao Shen
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

5.  Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.

Authors:  Gi-Ae Kim; Han Chu Lee; Min-Ju Kim; Yeonjung Ha; Eui Ju Park; Jihyun An; Danbi Lee; Ju Hyun Shim; Kang Mo Kim; Young-Suk Lim
Journal:  J Hepatol       Date:  2014-11-28       Impact factor: 25.083

6.  Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Authors:  Erik H C J Buster; Bettina E Hansen; George K K Lau; Teerha Piratvisuth; Stefan Zeuzem; Ewout W Steyerberg; Harry L A Janssen
Journal:  Gastroenterology       Date:  2009-09-06       Impact factor: 22.682

7.  Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients.

Authors:  Masashi Tatsukawa; Akinobu Takaki; Hidenori Shiraha; Kazuko Koike; Yoshiaki Iwasaki; Haruhiko Kobashi; Shin-Ichi Fujioka; Kohsaku Sakaguchi; Kazuhide Yamamoto
Journal:  BMC Cancer       Date:  2011-10-21       Impact factor: 4.430

Review 8.  Recombination in viruses: mechanisms, methods of study, and evolutionary consequences.

Authors:  Marcos Pérez-Losada; Miguel Arenas; Juan Carlos Galán; Ferran Palero; Fernando González-Candelas
Journal:  Infect Genet Evol       Date:  2014-12-23       Impact factor: 3.342

9.  Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma.

Authors:  Dong-Won Kim; Seoung-Ae Lee; Eung-Soo Hwang; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

10.  Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China.

Authors:  H W Zhang; J H Yin; Y T Li; C Z Li; H Ren; C Y Gu; H Y Wu; X S Liang; P Zhang; J F Zhao; X J Tan; W Lu; S Schaefer; G W Cao
Journal:  Gut       Date:  2008-08-28       Impact factor: 23.059

View more
  22 in total

1.  Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes.

Authors:  Masaki Kato; Susumu Hamada-Tsutsumi; Chiaki Okuse; Aiko Sakai; Nobuyuki Matsumoto; Masaaki Sato; Toshiyuki Sato; Mitsumi Arito; Kazuki Omoteyama; Naoya Suematsu; Kazuki Okamoto; Takanobu Kato; Fumio Itoh; Ryo Sumazaki; Yasuhito Tanaka; Hiroshi Yotsuyanagi; Tomohiro Kato; Manae Suzuki Kurokawa
Journal:  J Gastroenterol       Date:  2017-02-14       Impact factor: 7.527

Review 2.  Virus-induced hepatocellular carcinoma with special emphasis on HBV.

Authors:  Ming Wang; Dong Xi; Qin Ning
Journal:  Hepatol Int       Date:  2017-01-17       Impact factor: 6.047

3.  Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection.

Authors:  Benjamin Y Winer; Tiffany Huang; Benjamin E Low; Cindy Avery; Mihai-Alexandru Pais; Gabriela Hrebikova; Evelyn Siu; Luis Chiriboga; Michael V Wiles; Alexander Ploss
Journal:  Virology       Date:  2016-12-19       Impact factor: 3.616

4.  Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study.

Authors:  Qing-Wang Ye; Shu-Jie Pang; Ning Yang; Hai-Bin Zhang; Yong Fu; Bin Lin; Guang-Shun Yang
Journal:  J Gastrointest Surg       Date:  2019-06-13       Impact factor: 3.452

Review 5.  HBV replication inhibitors.

Authors:  Claire Pierra Rouviere; Cyril B Dousson; John E Tavis
Journal:  Antiviral Res       Date:  2020-05-05       Impact factor: 5.970

6.  Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Authors:  Carla S Coffin; Scott K Fung; Fernando Alvarez; Curtis L Cooper; Karen E Doucette; Claire Fournier; Erin Kelly; Hin Hin Ko; Mang M Ma; Steven R Martin; Carla Osiowy; Alnoor Ramji; Edward Tam; Jean Pierre Villeneuve
Journal:  Can Liver J       Date:  2018-12-25

7.  Hepatitis B Prevalence and Risk Factors in Punjab, India: A Population-Based Serosurvey.

Authors:  Shaun Shadaker; Ajit Sood; Francisco Averhoff; Anil Suryaprasad; Subodh Kanchi; Vandana Midha; Saleem Kamili; Muazzam Nasrullah; Adam Trickey; Ravinder Garg; Pramod Mittal; Suresh K Sharma; Peter Vickerman; Paige A Armstrong
Journal:  J Clin Exp Hepatol       Date:  2022-04-18

8.  Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection.

Authors:  Long-Bin Jeng; Tsai-Chung Li; Shih-Chao Hsu; Chiao-Fang Teng
Journal:  Viruses       Date:  2022-06-20       Impact factor: 5.818

9.  Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.

Authors:  Zilin Tang; Xiaodong Li; Shunquan Wu; Yan Liu; Yan Qiao; Dongping Xu; Jin Li
Journal:  Hepatol Int       Date:  2017-08-30       Impact factor: 6.047

10.  Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.

Authors:  Min Li; Tingting Lv; Shanshan Wu; Wei Wei; Xiaohai Wu; Xiaojuan Ou; Hong Ma; Shein-Chung Chow; Yuanyuan Kong; Hong You; Jidong Jia
Journal:  Hepatol Int       Date:  2020-01-03       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.